To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
Official Title
A Phase IV, Prospective, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Survival Benefits of Zemplar Relative to Calcijex in Subjects with Stage V Chronic Kidney Disease on Hemodialysis
Conditions
End-Stage Kidney Disease
Study Type
Observational
Study Design
Natural History, Longitudinal, Defined Population, Prospective Study
Further Details
Study Start
April 2003
Eligibility & Criteria
Criteria:- Stage V Chronic Kidney Disease Patients on Hemodialysis requiring treatment for secondary hyperparathyroidism with vitamin D therapy
Total Enrolment
2200
Contact Details
Julie Rock 847-937-3286 (US Only) or contact via email julie.rock@abbott.com
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.
Related Articles
A device to measure foot control is being…
Urologists are specialists who treat people for problems…
Study results published today in the National Kidney…
Need a health appointment?
Find and book a doctor, dentist, physio and more on Healthengine
Find a practitioner
